HK1220209A1 - 治疗急性肾损伤的方法 - Google Patents

治疗急性肾损伤的方法 Download PDF

Info

Publication number
HK1220209A1
HK1220209A1 HK16108216.3A HK16108216A HK1220209A1 HK 1220209 A1 HK1220209 A1 HK 1220209A1 HK 16108216 A HK16108216 A HK 16108216A HK 1220209 A1 HK1220209 A1 HK 1220209A1
Authority
HK
Hong Kong
Prior art keywords
methods
kidney injury
kidney
treating acute
acute kidney
Prior art date
Application number
HK16108216.3A
Other languages
English (en)
Chinese (zh)
Inventor
Richard A. ZAGER
Dennis ANDRESS
Original Assignee
Abbvie Inc.
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc., Fred Hutchinson Cancer Research Center filed Critical Abbvie Inc.
Publication of HK1220209A1 publication Critical patent/HK1220209A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16108216.3A 2013-03-08 2014-03-10 治疗急性肾损伤的方法 HK1220209A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775174P 2013-03-08 2013-03-08
US61/775,174 2013-03-08
PCT/US2014/022688 WO2014138738A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
HK1220209A1 true HK1220209A1 (zh) 2017-04-28

Family

ID=51492045

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108216.3A HK1220209A1 (zh) 2013-03-08 2014-03-10 治疗急性肾损伤的方法

Country Status (10)

Country Link
US (1) US20160015701A1 (OSRAM)
EP (1) EP2964671A4 (OSRAM)
JP (1) JP2016512201A (OSRAM)
CN (1) CN105324395A (OSRAM)
AU (1) AU2014225320A1 (OSRAM)
BR (1) BR112015020788A2 (OSRAM)
CA (1) CA2901922A1 (OSRAM)
HK (1) HK1220209A1 (OSRAM)
MX (1) MX2015011730A (OSRAM)
WO (1) WO2014138738A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
CN107106522A (zh) * 2014-11-07 2017-08-29 艾伯维公司 使用液体潴留的预测因子治疗ckd的方法
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
MY192385A (en) * 2016-10-05 2022-08-18 Mitobridge Inc Methods of treating acute kidney injury
KR102177349B1 (ko) * 2018-02-13 2020-11-12 서울대학교병원 체세포 복제 효율 증진용 조성물
US10978176B2 (en) 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
CA3160148A1 (en) * 2019-11-06 2021-05-14 Northwestern University Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury
KR20230015874A (ko) * 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
CN113209111A (zh) * 2021-05-14 2021-08-06 上海海糖生物医药科技有限公司 一种褐藻寡糖的应用
CN115005157B (zh) * 2022-06-02 2023-12-26 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN116731117B (zh) * 2023-06-19 2024-05-10 武汉大学 Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US20060100743A1 (en) * 2004-04-23 2006-05-11 Renal Diagnostic Inc. Automated non-invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Also Published As

Publication number Publication date
CA2901922A1 (en) 2014-09-12
AU2014225320A1 (en) 2015-08-06
EP2964671A4 (en) 2016-08-31
CN105324395A (zh) 2016-02-10
MX2015011730A (es) 2016-04-04
BR112015020788A2 (pt) 2017-10-10
JP2016512201A (ja) 2016-04-25
EP2964671A1 (en) 2016-01-13
US20160015701A1 (en) 2016-01-21
WO2014138738A1 (en) 2014-09-12
WO2014138738A8 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
WO2014138738A8 (en) Methods of treating acute kidney injury
FIC20250028I1 (fi) Eplonterseeni, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NO2025050I1 (no) Acalabrutinib or a pharmaceutically acceptable salt thereof, in combination with venetoclax optionally with or without obinutuzumab
Martel-Pelletier et al. Future therapeutics for osteoarthritis
NO2023038I1 (no) Ivosidenib or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof
NO2022059I1 (no) Lenacapavir or a pharmaceutically acceptable salt thereof, in particular lenacapavir sodium
NO2025017I1 (no) Acoramidis, and/or a pharmaceutically acceptable salt thereof, especially acoramidis hydrochloride
LUC00083I2 (en) Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
HK1207000A1 (en) Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
LT3317301T (lt) Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
CL2013003143A1 (es) Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-.
HK1243430A1 (zh) 通过施用il-6r拮抗剂治疗乾眼病的方法
EP3065712A4 (en) Microparticles, methods for their preparation and use
SG11201506358PA (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
MX2016000188A (es) Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan.
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
EP2959905A4 (en) ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
EP2959908A4 (en) ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
EP2959907A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE
FR3010432B1 (fr) Structure de securite, du genre echafaudage, pour le travail en elevation
Al-wazir E-government Implementation in Least Developed Countries: a Case Study of Yemen